Sermorelin
Sermorelin is the earlier, unmodified compound that CJC-1295 and Tesamorelin's stability modifications were built to improve on — and unlike most compounds referenced on this site, it has a completed pediatric FDA approval history.
Not currently stocked by KYIN Peptides, but available to order — see availability below.
What Is Sermorelin?
Sermorelin is a synthetic fragment corresponding to the first 29 amino acids of native growth-hormone-releasing hormone — GHRH(1-29). It retains full GHRH receptor bioactivity but is cleared from circulation quickly, which is precisely why later analogs like CJC-1295 and Tesamorelin were engineered with stability modifications for a longer half-life. See its full discovery history.
Research Focus
Sermorelin represents the foundational, unmodified GHRH signal that KYIN's stocked GHRH analogs build on. See our GHRH & Growth Hormone research overview for how it fits alongside CJC-1295 and Tesamorelin, our full CJC-1295 vs Tesamorelin vs Ipamorelin vs Sermorelin comparison, or how Hexarelin and Anamorelin compare as other non-stocked compounds in this category, or the now-stocked GHRP-6.
Clinical & Preclinical Trial Data
Unlike most compounds referenced on this site, sermorelin has a completed pediatric approval history. The pivotal trials supporting its FDA approval (as Geref, in a 110-patient trial of prepubertal children with idiopathic GH deficiency) found daily subcutaneous sermorelin increased height velocity from a baseline of 4.1 cm/year to 8.0 cm/year, with the effect sustained through 36 months of continuous therapy; 74% of treated children showed increased growth velocity after 6 months.
Geref was FDA-approved in 1990 (with a further approval in 1997) and later discontinued from the market in 2008 — a 2013 FDA determination confirmed the withdrawal was for commercial reasons, not safety or effectiveness. Sermorelin is now available only through compounding pharmacies rather than as an FDA-approved commercial product.
Availability
Sermorelin is not part of KYIN Peptides' standard catalogue, but it is available to order — contact us directly and we'll source it for you.
Sermorelin questions
What is Sermorelin?
Sermorelin is a synthetic fragment corresponding to the first 29 amino acids of native growth-hormone-releasing hormone, GHRH(1-29). It retains full GHRH receptor bioactivity but is cleared from circulation quickly, which is why later analogs like CJC-1295 and Tesamorelin were engineered for a longer half-life.
How is Sermorelin different from CJC-1295?
Sermorelin is the unmodified GHRH(1-29) fragment — it has full native bioactivity but is cleared from circulation quickly. CJC-1295 is a structurally modified version of the same GHRH signal, engineered specifically to resist that rapid degradation and extend its duration of action.
Was Sermorelin ever an approved drug?
Yes — as Geref, it was FDA-approved in 1990 (with a further approval in 1997) for pediatric growth hormone deficiency, but was discontinued from the market in 2008. A 2013 FDA determination confirmed the withdrawal was for commercial reasons, not safety or effectiveness. Sermorelin is now available only through compounding pharmacies rather than as an FDA-approved commercial product.
Does KYIN Peptides sell Sermorelin?
Not as part of our standard catalogue, but yes — it's available to order. Contact us directly and we'll source it for you.
Interested in sourcing Sermorelin?
Contact us and we'll help you source it, or browse our stocked GH-axis peptides.